Shilpa Medicare’s Formulations Facility Gets U.S. FDA Warning Letter
An Ascophenum-P tablet sits before packaging at OAO Pharmstandard’s Leksredstva drug manufacturing unit in Kursk, Russia. (Photographer: Andrey Rudakov/Bloomberg)

Shilpa Medicare’s Formulations Facility Gets U.S. FDA Warning Letter

Shilpa Medicare Ltd.'s formulations facility in Jadcherla, Telangana has received a warning letter from the U.S. Food and Drug Administration, the company stated in a filing to the exchanges.This i...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.